ClinicalTrials.gg
CompletedNCT03960957Updated Aug 26, 2022Results posted

Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines

A Phase 3 interventional study of AbobotulinumtoxinA and Placebo in Glabellar Frown Lines, sponsored by Galderma R&D. Completed at 11 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-26.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
301
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

An interventional phase 3 study to evaluate efficacy and safety of a new dilution and injection volume of AbobotulinumtoxinA treatment for glabellar lines

02

Conditions studied

  • Glabellar Frown Lines
03

In context

Lead sponsor

Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.

Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Moderate to severe glabellar lines at maximum frown
  • Understands the study requirements and signs an form

Exclusion criteria

Exclusion Criteria:

  • Botulinum toxin treatment in the face within 6 months prior to study treatment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
301 participants (actual)

Study arms

  • Experimental
    Experimental

    AbobotulinumtoxinA

    Biological: AbobotulinumtoxinA

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • Treatment of glabellar facial lines with 50 U AbobotulinumtoxinA

  • OtherPlacebo

    Treatment of glabellar facial lines with placebo

06

What researchers measure

Primary outcomes

  1. Evaluate Composite Responder Rate at Month 1 for a Single Dose of AbobotulinumtoxinA Compared to Placebo

    Composite responder is defined as a subject who achieves a score of 0 or 1 and at least 2 grades improvement on both the Investigator Live Assessment (ILA) and the Subject Self Assessment (SSA)

    Time frame: Month 1 after treatment

07

Results

Posted May 11, 2021

Participant flow

Participant flow — Overall Study
MilestoneExperimentalPlacebo
Started22477
Completed21671
Not completed86

Outcome measures

PrimaryEvaluate Composite Responder Rate at Month 1 for a Single Dose of AbobotulinumtoxinA Compared to Placebo

Composite responder is defined as a subject who achieves a score of 0 or 1 and at least 2 grades improvement on both the Investigator Live Assessment (ILA) and the Subject Self Assessment (SSA)

Time frame:
Month 1 after treatment
Reported as:
Count of participants · Participants
Evaluate Composite Responder Rate at Month 1 for a Single Dose of AbobotulinumtoxinA Compared to Placebo
ParticipantsExperimentalPlacebo
Evaluate Composite Responder Rate at Month 1 for a Single Dose of AbobotulinumtoxinA Compared to Placebo1420

Adverse events

Collected over 24 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental0/223 (0%)4/223 (1.8%)24/223 (10.8%)
Placebo0/77 (0%)0/77 (0%)6/77 (7.8%)
Most frequent serious events
Most frequent serious events
EventExperimentalPlacebo
Worsening knee painMusculoskeletal and connective tissue disorders1/2230/77
Acute diverticulitisInfections and infestations1/2230/77
Long QT syndromeCardiac disorders1/2230/77
Worsening of hemorrhoidsGastrointestinal disorders1/2230/77
Most frequent other events
Most frequent other events
EventExperimentalPlacebo
HeadacheNeoplasms benign, malignant and unspecified (incl cysts and polyps)19/2233/77
injection site painGeneral disorders1/2232/77
Eyelid ptosisEye disorders3/2230/77
Injection site discomfortGeneral disorders0/2231/77
sinus painRespiratory, thoracic and mediastinal disorders0/2231/77
MigraineNervous system disorders1/2230/77
Injection site reactionGeneral disorders1/2230/77

Baseline characteristics

Age, Continuous
Age, Continuous(years)ExperimentalPlaceboTotal
Mean44.7 ± 11.4342.5 ± 11.8644.1 ± 11.56
Sex: Female, Male
Sex: Female, Male(Participants)ExperimentalPlaceboTotal
Female19569264
Male29837
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ExperimentalPlaceboTotal
American Indian or Alaska Native000
Asian426
Native Hawaiian or Other Pacific Islander000
Black or African American9211
White20572277
More than one race404
Unknown or Not Reported213
Region of Enrollment
Region of Enrollment(participants)ExperimentalPlaceboTotal
United States22477301
Fitzpatrick Skin Type (FST)
Fitzpatrick Skin Type (FST)(Participants)ExperimentalPlaceboTotal
FST I415
FST II592180
FST III10740147
FST IV451358
FST V314
FST VI617
08

Study locations

11 sites
  • Galderma Study Site
    Redondo Beach, California 90277, United States
  • Galderma Study Site
    San Diego, California 92121, United States
  • Galderma Study Site
    Westport, Connecticut 06877, United States
  • Galderma Study Site
    Washington, District of Columbia 20037, United States
  • Galderma Study Site
    Coral Gables, Florida 33134, United States
  • Galderma Study Site
    Atlanta, Georgia 30342, United States
  • Galderma Study Site
    Saint Louis, Missouri 63103, United States
  • Galderma Study Site
    Omaha, Nebraska 68144, United States
  • Galderma Study Site
    Cincinnati, Ohio 45236, United States
  • Galderma Study Site
    Austin, Texas 78746, United States
  • Galderma Study Site
    Spring, Texas 77388, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Sep 2019, 3 months.

Results were first posted in May 2021, 1 year 7 months after primary completion. A results delay was requested in Jul 2020.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2019
First posted
May 23, 2019
StartActual
Jun 17, 2019
Primary completionActual
Sep 27, 2019
CompletionActual
Apr 16, 2020
Results delay requested
Jul 24, 2020
Results first posted
May 11, 2021
Last update
Aug 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03960957
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
May 23, 2019
Start date
Jun 17, 2019
Primary completion
Sep 27, 2019
Completion
Apr 16, 2020
Results posted
May 11, 2021
Last update
Aug 26, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion